Next Article in Journal
Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole–Indole Conjugates as Anticancer CDK Inhibitors
Next Article in Special Issue
Sulfur Compounds Inhibit High Glucose-Induced Inflammation by Regulating NF-κB Signaling in Human Monocytes
Previous Article in Journal
Effect of Angelica gigas Nakai Ethanol Extract and Decursin on Human Pancreatic Cancer Cells
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus

by
Dimitri Papukashvili
1,†,
Nino Rcheulishvili
1,† and
Yulin Deng
1,2,*
1
School of Life Science, Beijing Institute of Technology, Beijing 100081, China
2
Beijing Key Laboratory for Separation and Analysis in Biomedicine and Pharmaceuticals, Beijing 100081, China
*
Author to whom correspondence should be addressed.
These authors have contributed equally to this work.
Molecules 2020, 25(9), 2029; https://doi.org/10.3390/molecules25092029
Submission received: 26 March 2020 / Revised: 16 April 2020 / Accepted: 24 April 2020 / Published: 27 April 2020

Abstract

:
Creatine supplementation of the population with type 2 diabetes mellitus (T2DM) combined with an exercise program is known to be a possible therapy adjuvant with hypoglycemic effects. However, excessive administration of creatine leads to the production of methylamine which is deaminated by the enzyme semicarbazide-sensitive amine oxidase (SSAO) and as a result, cytotoxic compounds are produced. SSAO activity and reaction products are increased in the serum of T2DM patients. Creatine supplementation by diabetics will further augment the activity of SSAO. The current review aims to find a feasible way to ameliorate T2DM for patients who exercise and desire to consume creatine. Several natural agents present in food which are involved in the regulation of SSAO activity directly or indirectly are reviewed. Particularly, zinc-α2-glycoprotein (ZAG), zinc (Zn), copper (Cu), histamine/histidine, caffeine, iron (Fe), and vitamin D are discussed. Inhibiting SSAO activity by natural agents might reduce the potential adverse effects of creatine metabolism in population of T2DM.

1. Introduction

Diabetes is a chronic hyperglycemic disease. The population with type 2 diabetes mellitus (T2DM) is going to reach an alarming level soon [1,2]. It is most prevalent in subjects older than 45 years [3,4], however, the number of diabetes cases has increased in young people too [5]. To improve the glycemic condition, which is the main problem in diabetes condition, physical exercise therapy is necessary for all ages [6,7]. Creatine is a naturally produced nitrogenous molecule that improves physical strength in vertebrates [8]. Creatine facilitates recycling of adenosine triphosphate (ATP)- the energy currency of the cell, therefore, represents the key component of energy metabolism in muscle [9]. In the body, approximately 1 g/day of creatine is synthesized in the liver, pancreas, and kidneys from arginine, glycine, and methionine [10,11]. It is also obtained by ingesting foods such as red meat and seafood [12]. The body converts creatine into phosphocreatine and stores it in the muscles where it can be used as an energy source [13]. Furthermore, creatine is also made synthetically [14] and is one of the most popular natural supplements [15,16,17,18] used for improving muscle power, strength, and gaining lean mass [17,18,19,20]. For that reason, creatine and physical exercise are often referred together. Excessive creatine supplementation can elevate methylamine levels [21,22,23,24,25] which, as a substrate of semicarbazide-sensitive amine oxidase (SSAO), is oxidatively deaminated [26,27] and cytotoxic formaldehyde is produced [28,29]. Nevertheless, creatine supplementation does not impair kidney function in healthy individuals [30] and even in animals with pre-existing renal failure [31]. Gualano et al. showed that creatine supplementation combined with exercise alleviated glycemic conditions in T2DM [13]. Although creatine intake has a hypoglycemic effect, on the other hand, it might promote certain health risks accompanying its supplementation. SSAO-mediated deamination products, such as aldehydes, hydrogen peroxide (H2O2), ammonia, are produced, therefore, unfavorable health consequences might arise. Notably, SSAO activity in the blood plasma of diabetic patients is upregulated [32,33,34,35,36]. SSAO is a copper (Cu)-containing enzyme. There is evidence that serum Cu levels are elevated in T2DM cases [37]. Based on the aforementioned information, we assume that the prevention of possible adverse outcomes of creatine supplementation in T2DM patients is needed. SSAO inhibition may have a beneficial impact on creatine supplementation in diabetic patients. There are numbers of already well-known inhibitors capable to inhibit SSAO activity but most of them are toxic to some extent [38]. Interestingly, there are some natural compounds capable to lower increased SSAO activity. In this review, natural, relatively accessible, and possibly advantageous agents with respect to SSAO inhibition are discussed. The role of inhibitive effects on SSAO throughout the supplementation of creatine in T2DM patients is illustrated in Figure 1.

2. Creatine Supplementation and Type 2 Diabetes Mellitus

Creatine is an essential compound with a positive influence on brain function [39,40,41] and muscle performance [42]. Its estimated daily intake without a special diet is approximately 1 g/day, while 25–30 g/day can be achieved via special supplementation including a high protein diet [14]. It is accumulated in the body approximately 120–140 g in 70 kg young males, although, this amount varies individually according to the muscle fiber types, fat-free mass, etc. [15]. Because of ergogenic aids, it represents a popular nutritional supplement for athletes [10,15,17,43]. Creatine monohydrate and nitrate are prominent supplements used for improving exercise performance [44]. Other less popular supplements, as well as dietary sources, are presented in Table 1. Most of the studies are executed on creatine monohydrate. The effective loading dose of creatine monohydrate is 0.3 g/kg daily for 5–7 followed by the maintenance, 0.03 g/kg daily for approximately 6 weeks [45]. After administration, it is transported into the cells by the creatine transporter 1 (CreaT1). Afterward, it is being degraded spontaneously and a waste product creatinine is produced while via the action of creatinase sarcosine is generated; by sarcosine reductase methylamine is produced and then SSAO-mediated oxidation takes place [22].
Due to oral supplementation, creatine levels in the body are increased which is followed by the saturation of creatine into various cells or by clearing it from the blood via renal filtration [11]. Adverse effects may appear as a result of creatine supplementation overdosing by patients with potential risks or pre-existing disorders of renal diseases [23,55]. Methylamine, the metabolic product of creatine, is regarded to play an essential role in SSAO activity and, as a result, cytotoxic compounds are produced [56,57]. Nevertheless, methylamine produced by creatine supplementation (up to 20 g/day) in healthy subjects, is within normal limit values [11], meaning that, methylamine produced via intake of creatine up to 20 g/day does not impair kidney function [23]. Interestingly, creatinine is a break-down product of creatine and low serum creatinine is associated with the increased risk of T2DM [58,59]. Indeed, Nie et al. found creatine levels to be considerably decreased in T2DM rats [60]. Moreover, creatine consumption in T2DM cases along with an exercise program is known to be beneficial for blood glucose level regulation and glucose transporter protein, GLUT-4 expression [61,62]. Gualano et al. demonstrated that creatine supplementation has no adverse effect on kidney function in individuals with T2DM [61]. Instead, it even improves insulin sensitivity in animal models [62] and T2DM patients [63,64]. Therefore, creatine may be proposed as a beneficial sports supplement for T2DM. However, it might have negative effects concerning SSAO activity alteration.

3. Why Is Semicarbazide-Sensitive Amine Oxidase Activity Elevated in Type 2 Diabetes Mellitus?

T2DM is a pathology that implies impaired glucose transport in the cells [3]. The compensatory mechanisms are involved in this process. SSAO is overexpressed and its activity is increased [32]. Accordingly, the formation of cytotoxic compounds- formaldehyde, ammonia, and H2O2, which may have a deleterious influence on the body, is elevated [21,22]. H2O2 is involved in insulin mimicry that enhances glucose transport [65]. The mentioned mechanism works to compensate for the worsen glycemic condition which is common for diabetes. However, compounds with adverse effect are formed simultaneously that is associated with diabetes complications- cardiovascular diseases, stroke, etc. [66]. Thus, the scientists assumed that inhibiting SSAO activity will diminish the risks and complications in diabetes [38]. Certain natural compounds and elements discussed in this article and their impact on SSAO activity are given in Figure 2.

4. Role of Semicarbazide-Sensitive Amine Oxidase in Creatine Metabolism

SSAO is expressed in plasma, on the surface of endothelial cells and adipocytes [67]. Its substrate, methylamine, is not as toxic as it becomes in the presence of SSAO that induces deamination. Subsequently, cytotoxic compounds are produced [21,68]. The accumulation of those compounds in mice was found as a result of high concentrations of methylamine and enhanced activity of SSAO [21,69]. Poortmans et al. studied 21 g/day of creatine monohydrate oral supplementation in 20 healthy male individuals and revealed that high dose loading of creatine in a short period of time increased excreted levels of methylamine and formaldehyde, 9.2-fold and 4.5-fold in the urine, respectively. However, this level of methylamine is still below the upper limit value of the normal range [22]. Therefore, creatine administration within the recommended doses by healthy subjects does not pose a risk. Besides, Gualano et al. reported a positive effect of creatine supplementation and aerobic training on glucose tolerance in sedentary healthy males [70].

5. Semicarbazide-Sensitive Amine Oxidase Mediated Creatine Impact on Type 2 Diabetes Mellitus

Diabetes mellitus is a metabolic disease when blood glucose levels rise from the normal range due to hormone insulin-related disorders, such as obesity [2]. Obesity is an unhealthy condition that includes excess fat accumulation in the body. This metabolic disorder along with an inactive lifestyle and an unhealthy diet increases T2DM cases over the last decade [71]. Notably, according to the abovementioned, the enzyme SSAO levels are increased in this medical condition [32]. Thus, consuming creatine in diabetes will increase the production of methylamine [24] which will be oxidized by SSAO and converted into cytotoxic compounds [21,55,72]. These substances appear to be harmful to the body in case of excessive accumulation. Interestingly, formaldehyde is found to induce cognitive impairments in diabetes [73]. It is known that the concentration of methylamine is upregulated in some physiological and pathological conditions—the former implies pregnancy and the latter—diabetes mellitus, among many others [74]. SSAO activity in both type 1 and type 2 diabetic patients may be upregulated due to augmentation of its substrates concentrations [75]. It is also noteworthy that in diabetic patients with cardiovascular complications, elevated plasma activity of SSAO is reported [21,76].

6. Promising Agents Involved in Regulating Semicarbazide-Sensitive Amine Oxidase Activity

6.1. Ability of Caffeine to Inhibit Semicarbazide-Sensitive Amine Oxidase and Its Simultaneous Administration with Creatine

In consonance with all the information mentioned above, it can be presumed that an effective solution is needed for the prevention of adverse outcomes in diabetic patients. Hence, SSAO inhibition aids patients with diabetes to decrease the levels of toxic compounds. Caffeine is a natural substance with antioxidant capacity commonly consumed worldwide in daily life [77,78]. It has the ability of inhibiting SSAO as it contains an imidazole ring [68,79]. Most of the inhibitors of this enzyme react on the imidazoline-binding inhibitory site of SSAO [79]. Moreover, caffeine was found to be ingested by T2DM patients more than by non-diabetics to decrease disease-associated drowsiness [80,81]. Studies evidenced the positive impact of caffeine intake in the population with T2DM [82,83]. Neves et al. demonstrated that consumption of caffeine from coffee had a protective effect on mortality of women with diabetes [84]. Additionally, Wistar and Goto-Kakizaki (GK) rats were administered with 1 g/L of caffeine dissolved in drinking water for 4 months. A favorable influence on the spatial memory which is associated with hippocampus normal function was observed in T2DM animals [85]. Apart from that, there are numbers of human and animal studies regarding the beneficial properties of caffeine and caffeinated products for promoting weight loss [86,87]. Da Silva et al. have studied the influence of 1.5 mg/kg caffeine intake on blood glucose levels in T2DM individuals throughout the exercise. This dose showed to be efficient for glucose-intolerance management [88]. Olivieri and Tipton have shown that 0.1–10 mM caffeine can inhibit SSAO activity IC50 = 0.8 ± 0.3 mM in bovine serum [79]. This is a quite wide range, thus, more human studies are necessary to understand the safety and the most effective amount of caffeine to inhibit the enzyme significantly. Moreover, Che et al. also reported its inhibitory effect (50 mg/kg/day, i.p.) influence on SSAO activity in various tissues of Wistar rats after administration for 10 and 25 days [68]. Caffeine is relatively safe in most of the commercially available foods and drinks [89,90].
Inhibition of SSAO activity can protect cells from the cytotoxic damage associated with SSAO-methylamine reaction products in T2DM patients. Thus, caffeine consumption might balance the activity of SSAO in people with T2DM who supplement creatine. However, future researches are needed with a larger number of individuals as there are articles indicating caffeine unprepossessing influence on blood glucose levels in type 1 and type 2 diabetes mellitus [91,92,93]. This can be explained by caffeine’s inhibitive ability on SSAO activity. Consequently, less H2O2 is produced and, therefore, the level of insulin mimicry decreases which worsens glucose tolerance.
In diabetes creatine concentrations are significantly low [61]. Creatine supplementation along with exercise training improves the glycemic condition in T2DM as well as balances creatine levels [94]. SSAO-mediated cytotoxicity side effects exist, therefore, the intake of caffeine in this circumstance is logical. The safe daily dose of caffeine is 400 mg per day which corresponds to the amount presented in approximately up to 4 cups of coffee [95]. There is evidence of creatine and caffeine benefits when ingested combined in healthy humans [96]. Twelve healthy male subjects were ingested by creatine with 5 days abstinence from caffeine and then were given caffeine. The study revealed that caffeine had a beneficial impact on sprint performances when consumed after loading of creatine [97]. Nonetheless, most of the researches refer to their non-ergogenic effect [98,99,100,101,102]. As there are no articles published with respect to creatine and caffeine simultaneous supplementation neither by humans nor animal models with diabetes, it remains unclear. Moreover, caffeine consumption diminishes glucose uptake [103,104] as it reduces SSAO activity, and, as a result, the glycemic condition is exacerbated. The impact of caffeine and creatine separate consumption on healthy and diabetic conditions is presented in Table 2. Studies including treatment with creatine-caffeine concurrent supplementation in healthy subjects/animals are given in Table 3.

6.2. Histamine/Histidine- Good or Bad for Type 2 Diabetes Mellitus?

Histamine is a neurotransmitter in the body that contains an imidazole ring. The activity of this bioamine is closely related to lipolysis and SSAO metabolism. It improves the condition of leptin-resistance, thus plays an important role as an anorexigenic agent [112]. Although the enzyme diamine oxidase (DAO) is responsible for oxidizing histamine, SSAO activity is also found to be related to the catalysis of histamine oxidation [113]. Importantly, histidine, a precursor amino acid for histamine was observed to improve insulin sensitivity and ameliorate metabolic syndrome, hence, by regulating hepatic glucose output, it can assist in the glycemic control in diabetes [114]. Kimura et al. demonstrated that histidine can augment the suppression of glucose production in T2DM [115]. As the dietary histidine is suggested to ameliorate glycemic condition via its favorable effects on insulin sensitivity, administration of histidine-rich nutriments, which are mostly protein-containing food, can be considered [114]. Moreover, histidine levels along with creatine concentration are found to be significantly diminished in rats with T2DM [61]. Based on the evidence, Coppari et al. hypothesized the therapeutic effects of leptin treatment- a hormone which diminishes fat storage in adipocytes, for diabetes [116]. Interestingly histamine is known to ameliorate leptin-resistance [112] which occurs in diabetes [116]. However, increased plasma histamine levels are observed in diabetic patients [117]. Hence, the data about the histamine/histidine impact on T2DM remain conflicting [118]. Apart from the involvement in SSAO activity regulation, histamine/histidine concern remains unclear up till now.

6.3. Zinc-α2-glycoprotein/Zinc

Along with the referred substances, zinc-α2-glycoprotein (ZAG) —a major plasma protein is found to owe SSAO inhibitive capacity via binding the enzyme at the non-catalytic site and reducing its activity non-competitively [119]. In the body, it is a responsible factor in stimulating lipolysis [120]. Gong et al. studied human subjects as well as mice and demonstrated that the concentration of serum ZAG was inversely proportional to the body fat in humans and mice [121]. Changes in ZAG levels are closely related to obesity [122] and the associated comorbidities such as diabetes, obesity, polycystic ovary syndrome [123,124], non-alcoholic fatty acid liver disease (NAFLD), etc. [125]. Particularly, ZAG exhibits the attenuation of diseases associated with obesity, e.g., NAFLD [125,126]. NAFLD is a prevalent complication of T2DM [127]. ZAG can play a certain role in T2DM. Indeed, studies have demonstrated that this glycoprotein is connected with hyperglycemia, insulin resistance, and other health conditions common in diabetes [128]. Circulating ZAG in T2DM patients is presented in lower concentrations than in control subjects [129]. In addition, the elevated expression of ZAG is related to weight gain attenuation [130] which is a common condition for subjects with T2DM [131]. Furthermore, ZAG levels in obese subjects are low as well [132].
In accordance with all the mentioned information, it would be prudent to find a strategy of increasing ZAG levels in the body. Interestingly, some studies demonstrated that the concentration of zinc (Zn), which is a constituent of ZAG, was found to be decreased in the serum of diabetic patients [37,133,134]. Moreover, Zn is evidenced to have a beneficial impact on diabetes [135,136]. The studies give the rationale that Zn dietary intake might reduce T2DM risk and ameliorate this health complication. Agents positively affecting the elevation of ZAG respectively have an impact on SSAO through the indirect way, meaning that, increasing ZAG levels are related to diminishing SSAO activity. Thus, moderately increasing the administration of Zn-rich food can be used as a therapeutic strategy as Zn has promising potential in diabetes and, moreover, it might indirectly reduce SSAO activity which is associated with creatine consumption. Creatine and Zn combination as a supplement might merit future development after the necessary number of studies.

6.4. Copper

SSAO belongs to Cu-containing primary amine oxidases. The concentrations of Cu and the enzyme itself are found to be positively correlated and are elevated in plasma and serum of diabetic patients [37,137]. Indeed, Yang et al. demonstrated that the expression of Cu-dependent enzymes and SSAO were increased along with the adipocyte differentiation [138]. Diabetes is associated with obesity which, on the other hand, implies excessive number and size of differentiated adipocytes. Moreover, the study conducted on mice showed that the serum Cu status was significantly higher in diabetic than in non-diabetic mice [139]. Squitti et al. demonstrated significantly elevated Cu levels in patients with T2DM as compared to the healthy subjects [140]. Tanaka et al. demonstrated that the Cu-chelating agent tetrathiomolybdate reduced insulin resistance and improved glucose tolerance in diabetic mice [139]. As Cu-chelating agents are not presented in food, avoiding intake of Cu-rich dietary sources may contribute to ameliorating T2DM condition while creatine supplementation.

6.5. Role of Dietary Iron Along with Creatine Supplementation in Type 2 Diabetes Mellitus

Iron (Fe) body levels are positively associated with the risk of T2DM [141]. Indeed, the serum concentration was found to be markedly increased in T2DM patients [37]. Dutra et al. investigated the oxidation of aminoacetone along with Fe presence. Aminoacetone represents one of the substrates of SSAO, and its levels are found to be increased in diabetes [142]. With the simultaneous existence of Fe ions, aminoacetone oxidation and H2O2 formation were enhanced significantly [142]. This suggests that the high Fe intake increases the risk of T2DM [143]. In T2DM H2O2 production is already augmented via SSAO activity, thus, elevated Fe consumption causes additional cytotoxicity. As in diabetic subjects, Fe levels are furthermore elevated, accordingly, moderate limitation of Fe intake along with creatine supplementation seems to be coherent. Moreover, increased Fe levels are linked to cardiovascular disease which represents diabetes complication [144]. However, Fe deficiency is found in obesity- concomitant disorder of diabetes [145,146]. Apparently, studies in this direction merit the attention to shed light on the impact of simultaneous consumption of Fe and creatine.

6.6. Vitamin D

Vitamin D is known to aid the body to ameliorate insulin sensitivity and thus, a glycemic condition in T2DM [147]. Data show that vitamin D deficiency is a basis of diabetes [148]. Low vitamin D levels are found to be associated with many disorders, including T2DM and cardiovascular diseases [149]. The progression of these health disorders involves SSAO activity. Based on the evidence, vitamin D improves vascular function and decreases another amine oxidase—monoamine oxidase-A (MAO-A) levels [150]. Some of MAO inhibitors manifested to inhibit SSAO activity as well [151,152,153] which develops the basis that vitamin D may also influence SSAO activity. Besides, creatine and vitamin D are present together in seafood and dairy products. Moreover, vitamin D along with calcium intake shows an improvement of important antioxidant enzymes in oxidative stress- superoxide dismutase (SOD) and catalase (CAT) activities among other benefits in diabetic rats [154,155]. SOD neutralizes superoxide radicals while CAT is responsible for decomposition of H2O2 into water and oxygen. The deficiency of these enzymes causes the risk of diabetes as oxidative stress takes place [156,157,158]. It is also observed that vitamin D supplementation increases Zn uptake with possible formation of Zn-vitamin D complex [159]. Although there is no evidence regarding vitamin D and SSAO direct linkage, it can be assumed that creatine supplementation with vitamin D combination in T2DM seems quite promising.
Major dietary sources of vitamin D with the other discussed agents involved in SSAO activity regulation are presented in Table 4. However, the thermal processing of food will decrease the content [160,161], therefore, concurrent supplementation might be considered for a better outcome.

7. Conclusions and Future Perspectives

Evincing all the above information, the current article provides a strong basis for studies focusing on the effects of the agents capable to ameliorate SSAO-induced cytotoxicity with respect to creatine in T2DM. Creatine supplementation is related to the modulation of glucose uptake in diabetes, as well as elevation of methylamine deamination products due to increased SSAO activity. Creatine supplementation along with ameliorating SSAO-mediated cytotoxicity with natural agents in dietary sources or supplements appears to be reasonable. The minor toxicity, inexpensiveness, and high consumption in daily life make caffeine easily available strategy to reduce the possible cytotoxic effects of creatine in diabetes.
Nonetheless, creatine and caffeine have contrary effects in terms of hydration- retention, and excretion, respectively. Thus, in case of such combination, intake of a sufficient amount of water should be recommended. Apart from that, Zn as a constituent of ZAG and widely available element in food seems to be promising for diabetes therapy concerning the regulation of ZAG levels and consequently, SSAO inhibition. High dietary Zn intake might be negatively associated with diabetes complications. Besides, studies aiming regulation of Cu concentration in the body need to be considered as a high level of Cu is associated with SSAO increment. Vitamin D might be involved in SSAO activity regulation chain, hence, its supplementation effects along with creatine intake merit further consideration. Limiting dietary Fe administration with creatine supplementation seems rational. Unlike the mentioned agents, histamine and histidine warrant more caution. In obesity histamine and serum SSAO levels are negatively associated, while in diabetes, the opposite result occurs. The molecular mechanism of the histamine and SSAO linkage in diabetes remains unclear. Thus, the investigation of the described agents requires further development. Taken together, counterbalancing the potentially negative impact of creatine in T2DM condition with respect to SSAO by the reviewed agents, may neutralize the cytotoxic effects. Eliminating possible adverse outcomes of creatine supplementation via inhibiting SSAO activity might have a beneficial impact in T2DM population.

Author Contributions

All authors contributed substantially to the preparation of this review. D.P. collected the data, analyzed and wrote the original draft of the manuscript, N.R. was responsible for data writing and editing the manuscript, Y.D. was responsible for the conceptualization and guiding. All authors discussed and confirmed the final manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the Research and Development of Digital Diagnosis and Treatment Equipment Grant 2017YFC0108504.

Acknowledgments

We would like to thank Adil Farooq Lodhi for the valuable advices.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Ogurtsova, K.; da Rocha Fernandes, J.D.; Huang, Y.; Linnenkamp, U.; Guariguata, L.; Cho, N.H.; Cavan, D.; Shaw, J.E.; Makaroff, L.E. IDF Diabetes Atlas: Global Estimates for the Prevalence of Diabetes for 2015 and 2040. Diabetes Res. Clin. Pract. 2017, 128, 40–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Kharroubi, A.T. Diabetes Mellitus: The Epidemic of the Century. World J. Diabetes 2015, 6, 850–867. [Google Scholar] [CrossRef] [PubMed]
  3. Goyal, R.; Jialal, I. Diabetes Mellitus Type 2. Stat. Pearls 2020.
  4. Xu, G.; Liu, B.; Sun, Y.; Du, Y.; Snetselaar, L.G.; Hu, F.B.; Bao, W. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: Population based study. BMJ 2018, 362, k1497. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Mainous, A.G.; Diaz, V.A.; Everett, S.J. Assessing Risk for Development of Diabetes in Young Adults. Ann. Fam. Med. 2007, 5, 425–429. [Google Scholar] [CrossRef] [PubMed]
  6. Yanai, H.; Adachi, H.; Masui, Y.; Katsuyama, H.; Kawaguchi, A.; Hakoshima, M.; Waragai, Y.; Harigae, T.; Hamasaki, H.; Sakoa, A. Exercise Therapy for Patients with Type 2 Diabetes: A Narrative Review. J. Clin. Med. Res. 2018, 10, 365–369. [Google Scholar] [CrossRef] [Green Version]
  7. Colberg, S.R.; Sigal, R.J.; Fernhall, B.; Regensteiner, J.G.; Blissmer, B.J.; Rubin, R.R.; Chasan-Taber, L.; Albright, A.L.; Braun, B. Exercise and Type 2 Diabetes. Diabetes Care 2010, 33, e147–e167. [Google Scholar] [CrossRef] [Green Version]
  8. Schoch, R.D.; Willoughby, D.; Greenwood, M. The Regulation and Expression of the Creatine Transporter: A Brief Review of Creatine Supplementation in Humans and Animals. J. Int. Soc. Sports Nutr. 2006, 3, 60–66. [Google Scholar] [CrossRef] [Green Version]
  9. Arlin, J.B.; Bhardwaj, R.M.; Johnston, A.; Miller, G.J.; Bardin, J.; Macdougall, F.; Fernandes, P.; Shankland, K.; William, I.F.D.; Florence, A.J. Structure and Stability of Two Polymorphs of Creatine and Its Monohydrate. Cryst. Eng. Comm. 2014, 16, 8197–8204. [Google Scholar] [CrossRef] [Green Version]
  10. Allen, P.J. Creatine Metabolism and Psychiatric Disorders: Does Creatine Supplementation Have Therapeutic Value? Neurosci. Biobehav. Rev. 2012, 36, 1442–1462. [Google Scholar] [CrossRef] [Green Version]
  11. Cooper, R.; Naclerio, F.; Allgrove, J.; Jimenez, A. Creatine Supplementation with Specific View to Exercise/Sports Performance: An Update. J. Int. Soc. Sports. Nutr. 2012, 9, 33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Torok, Z.A.; Busekrus, R.B.; Hydock, D.S. Effects of Creatine Supplementation on Muscle Fatigue in Rats Receiving Doxorubicin Treatment. Nutr. Cancer. 2019, 11, 1–8. [Google Scholar] [CrossRef] [PubMed]
  13. Gualano, B.; De Salles Painneli, V.; Roschel, H.; Artioli, G.G.; Neves, M.; De Sá Pinto, A.L.; Da Silva, M.E.; Cunha, M.R.; Otaduy, M.C.; Leite, C.; et al. Creatine in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Med. Sci. Sports. Exerc. 2011, 43, 770–778. [Google Scholar] [CrossRef] [PubMed]
  14. Williamson, L.; New, D. How the use of creatine supplements can elevate serum creatinine in the absence of underlying kidney pathology. BMJ Case Rep. 2014, 2014, bcr2014204754. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Bemben, M.G.; Lamont, H.S. Creatine Supplementation and Exercise Performance: Recent Findings. Sports Med. 2005, 35, 107–125. [Google Scholar] [CrossRef] [PubMed]
  16. Meamar, R.; Maracy, M.; Nematollahi, S.; Yeroshalmi, S.; Zamani-Moghaddam, A.; Ghazvini, M.R. Effect of taking dietary supplement on hematological and biochemical parameters in male bodybuilders an equation model. Iran. J. Nurs. Midwifery. Res. 2015, 20, 681–688. [Google Scholar] [CrossRef] [PubMed]
  17. Butts, J.; Jacobs, B.; Silvis, M. Creatine Use in Sports. Sports Health 2018, 10, 31–34. [Google Scholar] [CrossRef]
  18. Casey, A.; Greenhaff, P.L. Does Dietary Creatine Supplementation Play a Role in Skeletal Muscle Metabolism and Performance? Am. J. Clin. Nutr. 2000, 72, 607S–617S. [Google Scholar] [CrossRef]
  19. Van Loon, L.J.; Oosterlaar, A.M.; Hartgens, F.; Hesselink, M.K.; Snow, R.J.; Wagenmakers, A.J. Effects of Creatine Loading and Prolonged Creatine Supplementation on Body Composition, Fuel Selection, Sprint and Endurance Performance in Humans. Clin. Sci (Lond) 2003, 104, 153–162. [Google Scholar] [CrossRef] [Green Version]
  20. Rawson, E.S.; Venezia, A.C. Use of creatine in the elderly and evidence for effects on cognitive function in young and old. Amino Acids 2011, 40, 1349–1362. [Google Scholar] [CrossRef]
  21. Yu, P.H.; Deng, Y. Potential Cytotoxic Effect of Chronic Administration of Creatine, a Nutrition Supplement to Augment Athletic Performance. Med. Hypotheses 2000, 54, 726–728. [Google Scholar] [CrossRef] [PubMed]
  22. Poortmans, J.R.; Kumps, A.; Duez, P.; Fofonka, A.; Carpentier, A.; Francaux, M. Effect of Oral Creatine Supplementation on Urinary Methylamine, Formaldehyde, and Formate. Med. Sci Sports Exerc 2005, 37, 1717–1720. [Google Scholar] [CrossRef] [PubMed]
  23. Kim, H.J.; Kim, C.K.; Carpentier, A.; Poortmans, J.R. Studies on the Safety of Creatine Supplementation. Amino Acids 2011, 40, 1409–1418. [Google Scholar] [CrossRef]
  24. Francaux, M.; Poortmans, J.R. Side Effects of Creatine Supplementation in Athletes. Int. J. Sports. Physiol. Perform. 2006, 1, 311–323. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Sale, C.; Harris, R.C.; Florance, J.; Kumps, A.; Sanvura, R.; Poortmans, J.R. Urinary Creatine and Methylamine Excretion Following 4 X 5 G X day(-1) or 20 X 1 G X day(-1) of Creatine Monohydrate for 5 Days. J. Sports Sci. 2009, 27, 759–766. [Google Scholar] [CrossRef] [PubMed]
  26. Deng, Y.; Yu, P.H. Simultaneous Determination of Formaldehyde and Methylglyoxal in Urine: Involvement of Semicarbazide-Sensitive Amine Oxidase-Mediated Deamination in Diabetic Complications. J. Chromatogr. Sci. 1999, 37, 317–322. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Noonan, T.; Lukas, S.; Peet, G.W.; Pelletier, J.; Panzenbeck, M.; Hanidu, A.; Mazurek, S.; Wasti, R.; Rybina, I.; Roma, T.; et al. The Oxidase Activity of Vascular Adhesion Protein-1 (VAP-1) Is Essential for Function. Am. J. Clin. Exp. Immunol. 2013, 2, 172–185. [Google Scholar]
  28. İnci, M.; Zararsız, İ.; Davarcı, M.; Görür, S. Toxic Effects of Formaldehyde on the Urinary System. Turk. J. Urol. 2013, 39, 48–52. [Google Scholar] [CrossRef]
  29. Wong, M.Y.W.; Saad, S.; Pollock, C.; Wong, M.G. Semicarbazide-Sensitive Amine Oxidase and Kidney Disease. Am. J. Physiol. Renal. Physiol. 2013, 305, F1637–F1644. [Google Scholar] [CrossRef] [Green Version]
  30. Lugaresi, R.; Leme, M.; de Salles Painelli, V.; Murai, I.H.; Roschel, H.; Sapienza, M.T.; Lancha Junior, A.H.; Gualano, B. Does long-term creatine supplementation impair kidney function in resistance-trained individuals consuming a high-protein diet? J. Int. Soc. Sports. Nutr. 2013, 10, 26. [Google Scholar] [CrossRef] [Green Version]
  31. Taes, Y.E.; Delanghe, J.R.; Wuyts, B.; van de Voorde, J.; Lameire, N.H. Creatine supplementation does not affect kidney function in an animal model with pre-existing renal failure. Nephrol. Dial. Transplant. 2003, 18, 258–264. [Google Scholar] [CrossRef] [Green Version]
  32. Garpenstrand, H.; Ekblom, J.; Bäcklund, L.B.; Oreland, L.; Rosenqvist, U. Elevated Plasma Semicarbazide-Sensitive Amine Oxidase (SSAO) Activity in Type 2 Diabetes Mellitus Complicated by Retinopathy. Diabet. Med. 1999, 16, 514–521. [Google Scholar] [CrossRef] [PubMed]
  33. Li, H.; Lin, H.; Nien, F.; Wu, V.; Jiang, Y. Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes. PLoS ONE 2016, 11, e0147981. [Google Scholar] [CrossRef] [PubMed]
  34. Karadi, I.; Meszaros, Z.; Csanyi, A.; Szombathy, T.; Hosszufalusi, N.; Romics, L.; Magyar, K. Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis. Clin. Chim. Acta 2002, 323, 139–146. [Google Scholar] [CrossRef]
  35. Nunes, S.F.; Figueiredo, I.V.; Soares, P.J.; Costa, N.E.; Lopes, M.C.; Caramona, M.M. Semicarbazide-sensitive amine oxidase activity and total nitrite and nitrate concentrations in serum: Novel biochemical markers for type 2 diabetes? Acta Diabetol. 2009, 46, 135–140. [Google Scholar] [CrossRef] [PubMed]
  36. Nunes, S.F.; Figueiredo, I.V.; Pereira, J.S.; Soares, P.J.; Caramona, M.M.; Callingham, B. Changes in the activities of semicarbazide-sensitive amine oxidase in inferior mesenteric artery segments and in serum of patients with type 2 diabetes. Acta Diabetol. 2010, 47, 179–182. [Google Scholar] [CrossRef]
  37. Atari-Hajipirloo, S.; Valizadeh, N.; Khadem-Ansari, M.H.; Rasmi, Y.; Kheradmand, F. Altered Concentrations of Copper, Zinc, and Iron are Associated With Increased Levels of Glycated Hemoglobin in Patients With Type 2 Diabetes Mellitus and Their First-Degree Relatives. Int. J. Endocrinol. Metab. 2016, 14, e33273. [Google Scholar] [CrossRef] [Green Version]
  38. Papukashvili, D.; Rcheulishvili, N.; Deng, Y. Attenuation of Weight Gain and Prevention of Associated Pathologies by Inhibiting SSAO. Nutrients 2020, 12, 184. [Google Scholar] [CrossRef] [Green Version]
  39. Adhihetty, P.J.; Beal, M.F. Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases. Neuromol. Med. 2008, 10, 275–290. [Google Scholar] [CrossRef] [Green Version]
  40. Duarte-Silva, S.; Neves-Carvalho, A.; Soares-Cunha, C.; Silva, J.M.; Teixeira-Castro, A.; Vieira, R.; Silva-Fernandes, A.; Maciel, P. Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3. Mov. Disord. 2018, 33, 815–826. [Google Scholar] [CrossRef]
  41. Avgerinos, K.I.; Spyrou, N.; Bougioukas, K.I.; Kapogiannis, D. Effects of creatine supplementation on cognitive function of healthy individuals: A systematic review of randomized controlled trials. Exp. Gerontol. 2018, 108, 166–173. [Google Scholar] [CrossRef] [PubMed]
  42. Gordon, A.; Hultman, E.; Kaijser, L.; Kristjansson, S.; Rolf, C.J.; Nyquist, O.; Sylvén, C. Creatine Supplementation in Chronic Heart Failure Increases Skeletal Muscle Creatine Phosphate and Muscle Performance. Cardiovasc. Res. 1995, 30, 413–418. [Google Scholar] [CrossRef]
  43. Sales, L.P.; Pinto, A.J.; Rodrigues, S.F.; Alvarenga, J.C.; Gonçalves, N.; Sampaio-Barros, M.M.; Benatti, F.B.; Gualano, B.; Rodrigues Pereira, R.M. Creatine supplementation (3g/day) and bone health in older women: A 2-year, randomized, placebo-controlled trial. J. Gerontol. A. Biol. Sci. Med. Sci. 2020, 75, 931–938. [Google Scholar] [CrossRef] [PubMed]
  44. Galvan, E.; Walker, D.K.; Simbo, S.Y.; Dalton, R.; Levers, K.; O’Connor, A.; Goodenough, C.; Barringer, N.D.; Greenwood, M.; Rasmussen, C.; et al. Acute and Chronic Safety and Efficacy of Dose Dependent Creatine Nitrate Supplementation and Exercise Performance. J. Int. Soc. Sports. Nutr. 2016, 13, 2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Hall, M.; Trojian, T.H. Creatine supplementation. Curr. Sports. Med. Rep. 2013, 12, 240–244. [Google Scholar] [CrossRef]
  46. Post, A.; Tsikas, D.; Bakker, S.J.L. Creatine is a Conditionally Essential Nutrient in Chronic Kidney Disease: A Hypothesis and Narrative Literature Review. Nutrients 2019, 11, 1044. [Google Scholar] [CrossRef] [Green Version]
  47. Kreider, R.B.; Kalman, D.S.; Antonio, J.; Ziegenfuss, T.N.; Wildman, R.; Collins, R.; Candow, D.G.; Kleiner, S.M.; Almada, A.L.; Lopez, H.L. International Society of Sports Nutrition position stand: Safety and efficacy of creatine supplementation in exercise, sport, and medicine. J. Int. Soc. Sports. Nutr 2017, 14, 18. [Google Scholar] [CrossRef]
  48. Inácio, S.G.; de Oliveira, G.V.; Alvares, T.S. Caffeine and Creatine Content of Dietary Supplements Consumed by Brazilian Soccer Players. Int. J. Sport. Nutr. Exerc. Metab. 2016, 26, 323–329. [Google Scholar] [CrossRef]
  49. Buford, T.W.; Kreider, R.B.; Stout, J.R.; Greenwood, M.; Campbell, B.; Spano, M.; Ziegenfuss, T.; Lopez, H.; Landis, J.; Antonio, J. International Society of Sports Nutrition position stand: Creatine supplementation and exercise. J. Int. Soc. Sports. Nutr. 2007, 4, 6. [Google Scholar] [CrossRef] [Green Version]
  50. Gufford, B.T.; Sriraghavan, K.; Miller, N.J.; Miller, D.W.; Gu, X.; Vennerstrom, J.L.; Robinson, D.H. Physicochemical characterization of creatine N-methylguanidinium salts. J. Diet. Suppl. 2010, 7, 240–252. [Google Scholar] [CrossRef]
  51. Gufford, B.T.; Ezell, E.L.; Robinson, D.H.; Miller, D.W.; Miller, N.J.; Gu, X.; Vennerstrom, J.L. pH-Dependent Stability of Creatine Ethyl Ester: Relevance to Oral Absorption. J. Diet. Suppl. 2013, 10, 241–251. [Google Scholar] [CrossRef] [PubMed]
  52. Jagim, A.R.; Oliver, J.M.; Sanchez, A.; Galvan, E.; Fluckey, J.; Riechman, S.; Greenwood, M.; Kelly, K.; Meininger, C.; Rasmussen, C.; et al. A buffered form of creatine does not promote greater changes in muscle creatine content, body composition, or training adaptations than creatine monohydrate. J. Int. Soc. Sports. Nutr. 2012, 9, 43. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Gill, N.D.; Hall, R.D.; Blazevich, A.J. Creatine serum is not as effective as creatine powder for improving cycle sprint performance in competitive male team-sport athletes. J. Strength. Cond. Res. 2004, 18, 272–275. [Google Scholar] [PubMed]
  54. Selsby, J.T.; DiSilvestro, R.A.; Devor, S.T. Mg2+-creatine chelate and a low-dose creatine supplementation regimen improve exercise performance. J. Strength. Cond. Res. 2004, 18, 311–315. [Google Scholar] [PubMed]
  55. Davani-Davari, D.; Karimzadeh, I.; Ezzatzadegan-Jahromi, S.; Mahdi Sagheb, M. Potential Adverse Effects of Creatine Supplement on the Kidney in Athletes and Bodybuilders. Iran. J. Kidney. Dis. 2018, 12, 253–260. [Google Scholar]
  56. Jonas, S.K.; Riley, P.A.; Willson, R.L. Hydrogen Peroxide Cytotoxicity. Low-Temperature Enhancement by Ascorbate or Reduced Lipoate. Biochem. J. 1989, 264, 651–655. [Google Scholar] [CrossRef]
  57. Quievryn, G.; Zhitkovich, A. Loss of DNA-protein crosslinks from formaldehyde-exposed cells occurs through spontaneous hydrolysis and an active repair process linked to proteosome function. Carcinogenesis 2000, 21, 1573–1580. [Google Scholar] [CrossRef]
  58. Hjelmesæth, J.; Røislien, J.; Nordstrand, N.; Hofsø, D.; Hager, H.; Hartmann, A. Low serum creatinine is associated with type 2 diabetes in morbidly obese women and men: A cross-sectional study. BMC Endocr. Disord. 2010, 10, 6. [Google Scholar] [CrossRef] [Green Version]
  59. Harita, N.; Hayashi, T.; Kogawa Sato, K.; Nakamura, Y.; Yoneda, T.; Endo, G.; Kambe, H. Lower Serum Creatinine Is a New Risk Factor of Type 2 Diabetes. The Kansai Healthcare Study. Diabetes Care 2009, 32, 424–426. [Google Scholar] [CrossRef] [Green Version]
  60. Nie, Q.; Chen, H.; Hu, J.; Gao, H.; Fan, L.; Long, Z.; Nie, S. Arabinoxylan Attenuates Type 2 Diabetes by Improvement of Carbohydrate, Lipid, and Amino Acid Metabolism. Mol. Nutr. Food. Res. 2018, 62, e1800222. [Google Scholar] [CrossRef]
  61. Gualano, B.; De Salles Painelli, V.; Roschel, H.; Lugaresi, R.; Dorea, E.; Artioli, G.G.; Lima, F.R.; da Silva, M.E.; Cunha, M.R.; Seguro, A.C.; et al. Creatine supplementation does not impair kidney function in type 2 diabetic patients: A randomized, double-blind, placebo-controlled, clinical trial. Eur. J. Appl. Physiol. 2011, 111, 749–756. [Google Scholar] [CrossRef] [PubMed]
  62. Op’t Eijnde, B.; Jijakli, H.; Hespel, P.; Malaisse, W.J. Creatine supplementation increases soleus muscle creatine content and lowers the insulinogenic index in an animal model of inherited type 2 diabetes. Int. J. Mol. Med. 2006, 17, 1077–1084. [Google Scholar] [CrossRef] [PubMed]
  63. Alves, C.R.; Ferreira, J.C.; De Siqueira-Filho, M.A.; Carvalho, C.R.; Lancha, A.H., Jr.; Gualano, B. Creatine-induced glucose uptake in type 2 diabetes: A role for AMPK-α? Amino Acids 2012, 43, 1803–1807. [Google Scholar] [CrossRef] [PubMed]
  64. Ročić, B.; Znaor, A.; Ročić, P.; Weber, D.; Vučić Lovrenčić, M. Comparison of antihyperglycemic effects of creatine and glibenclamide in type II diabetic patients. Wien. Med. Wochenschr. 2011, 161, 519–523. [Google Scholar]
  65. Zorzano, A.; Abella, A.; Marti, L.; Carpéné, C.; Palacín, M.; Testar, X. Semicarbazide-sensitive amine oxidase activity exerts insulin-like effects on glucose metabolism and insulin-signaling pathways in adipose cells. Biochim. Biophys. Acta. 2003, 1647, 3–9. [Google Scholar] [CrossRef]
  66. Stolen, C.M.; Madanat, R.; Marti, L.; Kari, S.; Gennady, G.; Yegutkin, H.S.; Zorzano, A.; Jalkanen, S. Semicarbazide-sensitive amine oxidase overexpression has dual consequences: Insulin mimicry and diabetes-like complications. FASEB J. 2004, 18, 702–704. [Google Scholar] [CrossRef]
  67. Stolen, C.M.; Yegutkin, G.G.; Kurkijärvi, R.; Bono, P.; Alitalo, K.; Jalkanen, S. Origins of Serum Semicarbazide-Sensitive Amine Oxidase. Circ. Res. 2004, 95, 50–57. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Baoquan, C.; Wang, L.; Zhang, Z.; Zhang, Y.; Deng, Y. Distribution and Accumulation of Caffeine in Rat Tissues and Its Inhibition on Semicarbazide-Sensitive Amine Oxidase. Neurotoxicology 2012, 33, 1248–1253. [Google Scholar]
  69. Wang, L.; Xiao, S.; Li, Y.; Wang, L.; Che, B.; Zhao, X.; Deng, Y. Potential Toxicity of Chronic Creatine Supplementation in Mice. In Proceedings of the 3rd International Conference on Bioinformatics and Biomedical Engineering (ICBBE 2009), Beijing, China, 11–13 June 2009; IEEE: Beijing, China, 2009. [Google Scholar] [CrossRef]
  70. Gualano, B.; Novaes, R.B.; Artioli, G.G.; Freire, T.O.; Coelho, D.F.; Scagliusi, F.B.; Rogeri, P.S.; Roschel, H.; Ugrinowitsch, C.; Lancha, A.H. Effects of creatine supplementation on glucose tolerance and insulin sensitivity in sedentary healthy males undergoing aerobic training. Amino Acids 2008, 34, 245–250. [Google Scholar] [CrossRef]
  71. Reinehr, T. Inflammatory markers in children and adolescents with type 2 diabetes mellitus. Clin. Chim. Acta 2019, 496, 100–107. [Google Scholar] [CrossRef]
  72. Yu, P.H.; Wang, M.; Deng, Y.; Fan, H.; Shira-Bock, L. Involvement of Semicarbazide-Sensitive Amine Oxidase-Mediated Deamination in Atherogenesis in KKAy Diabetic Mice Fed with High Cholesterol Diet. Diabetologia 2002, 45, 1255–1262. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Tan, T.; Zhang, Y.; Luo, W.; Lv, J.; Han, C.; Hamlin, J.N.R.; Luo, H.; Li, H.; Wan, Y.; Yang, X.; et al. Formaldehyde induces diabetes-associated cognitive impairments. FASEB J. 2018, 32, 3669–3679. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Boor, P.J.; Trent, M.B.; Lyles, G.A.; Tao, M.; Ansari, G.A. Methylamine Metabolism to Formaldehyde by Vascular Semicarbazide-Sensitive Amine Oxidase. Toxicology 1992, 73, 251–258. [Google Scholar] [CrossRef]
  75. Obata, T. Diabetes and Semicarbazide-Sensitive Amine Oxidase (SSAO) Activity: A Review. Life Sci. 2006, 79, 417–422. [Google Scholar] [CrossRef] [PubMed]
  76. Magyar, K.; Mészáros, Z. Semicarbazide-Sensitive Amine Oxidase (SSAO): Present and Future. Inflammopharmacology 2003, 11, 165–173. [Google Scholar] [CrossRef] [PubMed]
  77. Nilnumkhum, A.; Rattiyaporn, K.; Sunisa, Y.; Visith, T. Caffeine Inhibits Hypoxia-Induced Renal Fibroblast Activation by Antioxidant Mechanism. Cell Adh. Migr. 2019, 13, 260–272. [Google Scholar] [CrossRef] [Green Version]
  78. Cappelletti, S.; Daria, P.; Sani, G.; Aromatario, M. Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug? Curr. Neuropharmacol. 2015, 13, 71–88. [Google Scholar] [CrossRef] [Green Version]
  79. Olivieri, A.; Tipton, K. Inhibition of Bovine Plasma Semicarbazide-Sensitive Amine Oxidase by Caffeine. J. Biochem. Mol. Toxicol. 2011, 25, 26–27. [Google Scholar] [CrossRef]
  80. Urry, E.; Jetter, A.; Holst, S.C.; Berger, W.; Spinas, G.A.; Langhans, W.; Landolt, H.P. A case-control field study on the relationships among type 2 diabetes, sleepiness and habitual caffeine intake. J. Psychopharmacol. 2017, 31, 233–242. [Google Scholar] [CrossRef]
  81. Urry, E.; Jetter, A.; Landolt, H.P. Assessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake. Nutr. Metab. (Lond) 2016, 13, 66. [Google Scholar] [CrossRef] [Green Version]
  82. Chrysant, S.G. The impact of coffee consumption on blood pressure, cardiovascular disease and diabetes mellitus. Expert Rev. Cardiovasc. Ther. 2017, 15, 151–156. [Google Scholar] [CrossRef]
  83. Gao, F.; Zhang, Y.; Ge, S.; Lu, H.; Chen, R.; Fang, P.; Shen, Y.; Wang, C.; Jia, W. Coffee consumption is positively related to insulin secretion in the Shanghai High-Risk Diabetic Screen ( SHiDS) Study. Nutr. Metab. (Lond) 2018, 15, 84. [Google Scholar] [CrossRef] [Green Version]
  84. Neves, J.S.; Leitão, L.; Magriço, R.; Vieira, M.B.; Dias, C.V.; Oliveira, A.; Carvalho, D.; Claggett, B. Caffeine consumption and mortality in diabetes: An analysis of NHANES 1999-2010. Front. Endocrinol. (Lausanne) 2018, 9, 547. [Google Scholar] [CrossRef]
  85. Duarte, J.M.N.; Skoug, C.; Silva, H.B.; Carvalho, R.A.; Gruetter, R.; Cunha, R.A. Impact of Caffeine Consumption on Type 2 Diabetes-Induced Spatial Memory Impairment and Neurochemical Alterations in the Hippocampus. Front. Neurosci. 2019, 12, 1015. [Google Scholar] [CrossRef] [PubMed]
  86. Rustenbeck, I.; Lier-Glaubitz, V.; Willenborg, M.; Eggert, F.; Engelhardt, U.; Jörns, A. Effect of chronic coffee consumption on weight gain and glycaemia in a mouse model of obesity and type 2 diabetes. Nutr. Diabetes. 2014, 30, e123. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Al-Goblan, A.S.; Al-Alfi, M.A.; Khan, M.Z. Mechanism linking diabetes mellitus and obesity. Diabetes. Metab. Syndr. Obes. 2014, 7, 587–591. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  88. Da Silva, L.A.; de Freitas, L.; Medeiros, T.E.; Osiecki, R.; Garcia Michel, R.; Snak, A.L.; Malfatti, C.R. Caffeine modifies blood glucose availability during prolonged low-intensity exercise in individuals with type-2 diabetes. Colomb. Med. (Cali) 2014, 45, 72–76. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  89. Temple, J.L.; Bernard, C.; Lipshultz, S.E.; Czachor, J.D.; Westphal, J.A.; Mestre, M.A. The Safety of Ingested Caffeine: A Comprehensive Review. Front. Psychiatry. 2017, 8, 80. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  90. Erukainure, O.L.; Ijomone, O.M.; Oyebode, O.A.; Chukwuma, C.I.; Aschner, M.; Islam, M.S. Hyperglycemia-Induced Oxidative Brain Injury: Therapeutic Effects of Cola Nitida Infusion against Redox Imbalance, Cerebellar Neuronal Insults, and Upregulated Nrf2 Expression in Type 2 Diabetic Rats. Food Chem. Toxicol. 2019, 127, 206–217. [Google Scholar] [CrossRef]
  91. Dewar, L.; Heuberger, R. The effect of acute caffeine intake on insulin sensitivity and glycemic control in people with diabetes. Diabetes Metab. Syndr. 2017, 2, S631–S635. [Google Scholar] [CrossRef]
  92. Lane, J.D.; Barkauskas, C.E.; Surwit, R.S.; Feinglos, M.N. Caffeine impairs glucose metabolism in type 2 diabetes. Diabetes Care 2004, 27, 2047–2048. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Shi, X.; Xue, W.; Liang, S.; Zhao, J.; Zhang, X. Acute caffeine ingestion reduces insulin sensitivity in healthy subjects: A systematic review and meta-analysis. Nutr. J. 2016, 15, 103. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Pinto, C.L.; Botelho, P.B.; Pimentel, G.D.; Campos-Ferraz, P.L.; Mota, J.F. Creatine supplementation and glycemic control: A systematic review. Amino Acids 2016, 48, 2103–2129. [Google Scholar] [CrossRef]
  95. Nawrot, P.; Jordan, S.; Eastwood, J.; Rotstein, J.; Hugenholtz, A.; Feeley, M. Effects of Caffeine on Human Health. Food Addit. Contam. 2003, 20, 1–30. [Google Scholar] [CrossRef] [PubMed]
  96. Doherty, M.; Smith, P.M.; Davison, R.C.; Hughes, M.G. Caffeine is ergogenic after supplementation of oral creatine monohydrate. Med. Sci. Sports. Exerc. 2002, 34, 1785–1792. [Google Scholar] [CrossRef]
  97. Lee, C.L.; Lin, J.C.; Cheng, C.F. Effect of caffeine ingestion after creatine supplementation on intermittent high-intensity sprint performance. Eur. J. Appl. Physiol. 2011, 111, 1669–1677. [Google Scholar] [CrossRef]
  98. Grosso, G.; Godos, J.; Galvano, F.; Giovannucci, E.L. Coffee, Caffeine, and Health Outcomes: An Umbrella Review. Annu. Rev. Nutr. 2017, 37, 131–156. [Google Scholar] [CrossRef] [Green Version]
  99. Trexler, E.T.; Smith-Ryan, A.E.; Roelofs, E.J.; Hirsch, K.R.; Persky, A.M.; Mock, M.G. Effects of Coffee and Caffeine Anhydrous Intake During Creatine Loading. J. Strength. Cond. Res. 2016, 30, 1438–1446. [Google Scholar] [CrossRef] [Green Version]
  100. Trexler, E.T.; Smith-Ryan, A.E. Creatine and caffeine: Considerations for concurrent supplementation. Int. J. Sport. Nutr. Exerc. Metab. 2015, 25, 607–623. [Google Scholar] [CrossRef]
  101. Tarnopolsky, M.A. Caffeine and creatine use in sport. Ann. Nutr. Metab. 2010, 57, 1–8. [Google Scholar] [CrossRef]
  102. Franco, F.S.C.; Costa, N.M.; Ferreira, S.A.; Carneiro-junior, M.A.; Natali, A.J. The effects of a high dosage of creatine and caffeine supplementation on the lean body mass composition of rats submitted to vertical jumping training. J. Int. Soc. Sports. Nutr. 2011, 8, 3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  103. Akash, M.S.H.; Rehman, K.; Chen, S. Effects of coffee on type 2 diabetes mellitus. Nutrition 2014, 30, 755–763. [Google Scholar] [CrossRef] [PubMed]
  104. Lee, S.; Hudson, R.; Kilpatrick, K.; Graham, T.E.; Ross, R. Caffeine ingestion is associated with reductions in glucose uptake independent of obesity and type 2 diabetes before and after exercise training. Diabetes Care 2005, 28, 566–572. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  105. Kutz, M.R.; Gunter, M.J. Creatine monohydrate supplementation on body weight and percent body fat. Strength. Cond. Res. 2003, 17, 817–821. [Google Scholar]
  106. Schäfer, L.U.; Hayes, M.; Dekerle, J. Creatine supplementation improves performance above critical power but does not influence the magnitude of neuromuscular fatigue at task failure. Exp. Physiol. 2019, 104, 1881–1891. [Google Scholar] [CrossRef] [PubMed]
  107. Icken, D.; Feller, S.; Engeli, S.; Mayr, A.; Müller, A.; Hilbert, A.; de Zwaan, M. Caffeine intake is related to successful weight loss maintenance. Eur. J. Clin. Nutr. 2016, 70, 532–534. [Google Scholar] [CrossRef]
  108. Seal, A.D.; Bardis, C.N.; Gavrieli, A.; Grigorakis, P.; Adams, J.D.; Arnaoutis, G.; Yannakoulia, M.; Kavouras, S.A. Coffee with High but Not Low Caffeine Content Augments Fluid and Electrolyte Excretion at Rest. Front. Nutr. 2017, 4, 40. [Google Scholar] [CrossRef] [Green Version]
  109. Jodra, P.; Lago-Rodríguez, A.; Sánchez-Oliver, A.J.; López-Samanes, A.; Pérez-López, A.; Veiga-Herreros, P.; San Juan, A.F.; Domínguez, R. Effects of caffeine supplementation on physical performance and mood dimensions in elite and trained-recreational athletes. J. Int. Soc. Sports. Nutr. 2020, 17, 2. [Google Scholar] [CrossRef] [Green Version]
  110. Sacramento, J.F.; Ribeiro, M.J.; Yubero, S.; Melo, B.F.; Obeso, A.; Guarino, M.P.; Gonzalez, C.; Conde, S.V. Disclosing caffeine action on insulin sensitivity: Effects on rat skeletal muscle. Eur. J. Pharm. Sci. 2015, 70, 107–116. [Google Scholar] [CrossRef]
  111. Urzúa, Z.; Trujillo, X.; Huerta, M.; Trujillo-Hernández, B.; Ríos-Silva, M.; Onetti, C.; Ortiz-Mesina, M.; Sánchez-Pastor, E. Effects of chronic caffeine administration on blood glucose levels and on glucose tolerance in healthy and diabetic rats. J. Int. Med. Res. 2012, 40, 2220–2230. [Google Scholar] [CrossRef]
  112. Jørgensen, E.A.; Knigge, U.; Warberg, J.; Kjaer, A. Histamine and the regulation of body weight. Neuroendocrinology 2007, 86, 210–214. [Google Scholar] [CrossRef]
  113. Iffiú-Soltész, Z.; Wanecq, E.; Prévot, D.; Grès, S.; Carpéné, C. Histamine oxidation in mouse adipose tissue is controlled by the AOC3 gene-encoded amine oxidase. Inflamm. Res. 2010, 59, S227–S229. [Google Scholar] [CrossRef] [PubMed]
  114. DiNicolantonio, J.J.; McCarty, M.F.; OKeefe, J.H. Role of dietary histidine in the prevention of obesity and metabolic syndrome. Open Heart 2018, 5, e000676. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  115. Kimura, K.; Nakamura, Y.; Inaba, Y.; Matsumoto, M.; Kido, Y.; Asahara, S.; Matsuda, T.; Watanabe, H.; Maeda, A.; Inagaki, F.; et al. Histidine augments the suppression of hepatic glucose production by central insulin action. Diabetes 2013, 62, 2266–2277. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  116. Coppari, R.; Bjørbæk, C. Leptin revisited: Its mechanism of action and potential for treating diabetes. Nat. Rev. Drug. Discov. 2012, 11, 692–708. [Google Scholar] [CrossRef] [Green Version]
  117. Pini, A.; Verta, R.; Grange, C.; Gurrieri, M.; Rosa, A.C. Histamine and diabetic nephropathy: An up-to-date overview. Clin. Sci. (Lond). 2019, 133, 41–54. [Google Scholar] [CrossRef]
  118. Koh, A.; Molinaro, A.; Ståhlman, M.; Khan, M.T.; Schmidt, C.; Mannerås-Holm, L.; Wu, H.; Carreras, A.; Jeong, H.; Olofsson, L.E.; et al. Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1. Cell 2018, 175, 947–961.e17. [Google Scholar] [CrossRef] [Green Version]
  119. Romauch, M. Zinc-α2-glycoprotein is an inhibitor of amine oxidase copper-containing 3. Open Biol. 2019, 9, 190035. [Google Scholar] [CrossRef] [Green Version]
  120. Hassan, M.I.; Waheed, A.; Yadav, S.; Singh, T.P.; Ahmad, F. Zinc alpha 2-glycoprotein: A multidisciplinary protein. Mol. Cancer. Res. 2008, 6, 892–906. [Google Scholar] [CrossRef] [Green Version]
  121. Gong, F.Y.; Zhang, S.J.; Deng, J.Y.; Zhu, H.J.; Pan, H.; Li, N.S.; Shi, Y.F. Zinc-alpha2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. Int. J. Obes. (Lond) 2009, 33, 1023–1030. [Google Scholar] [CrossRef] [Green Version]
  122. Mracek, T.; Gao, D.; Tzanavari, T.; Bao, Y.; Xiao, X.; Stocker, C.; Trayhurn, P.; Bing, C. Downregulation of zinc-{alpha}2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumour necrosis factor-alpha in adipocytes. J. Endocrinol. 2010, 204, 165–172. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  123. Xiao, X.H.; Qi, X.Y.; Li, J.; Wang, Y.B.; Wang, Y.D.; Liao, Z.Z.; Yang, J.; Ran, L.; Wen, G.B.; Liu, J.H. Serum zinc-α2-glycoprotein levels are elevated and correlated with thyroid hormone in newly diagnosed hyperthyroidism. BMC Endocr. Disord. 2019, 19, 12. [Google Scholar] [CrossRef] [PubMed]
  124. Liu, M.; Zhu, H.; Dai, Y.; Pan, H.; Li, N.; Wang, L.; Yang, H.; Yan, K.; Gong, F. Zinc-α2-Glycoprotein Is Associated with Obesity in Chinese People and HFD-Induced Obese Mice. Front. Physiol. 2018, 7, 62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  125. Li, C.; Li, J.; Chen, Y.; Zhong, X.; Kang, M. Effect of curcumin on visfatin and zinc-α2-glycoprotein in a rat model of non-alcoholic fatty liver disease. Acta. Cir. Bras. 2016, 31, 706–713. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  126. Liu, T.; Luo, X.; Li, Z.H.; Wu, J.C.; Luo, S.Z.; Xu, M.Y. Zinc-α2-glycoprotein 1 attenuates non-alcoholic fatty liver disease by negatively regulating tumour necrosis factor-α. World J. Gastroenterol. 2019, 25, 5451–5468. [Google Scholar] [CrossRef] [PubMed]
  127. Dharmalingam, M.; Yamasandhi, P.G. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian. J. Endocrinol. Metab. 2018, 22, 421–428. [Google Scholar] [CrossRef]
  128. Yang, M.; Liu, R.; Li, S.; Luo, Y.; Zhang, Y.; Zhang, L.; Liu, D.; Wang, Y.; Xiong, Z.; Boden, G.; et al. Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: Cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes. Diabetes Care 2013, 36, 1074–1082. [Google Scholar]
  129. Tian, M.; Liang, Z.; Liu, R.; Li, K.; Tan, X.; Luo, Y.; Yang, M.; Gu, H.F.; Liu, H.; Li, L.; et al. Effects of sitagliptin on circulating zinc-α2-glycoprotein levels in newly diagnosed type 2 diabetes patients: A randomized trial. Eur. J. Endocrinol. 2016, 174, 147–155. [Google Scholar] [CrossRef]
  130. Bing, C.; Mracek, T.; Gao, D.; Trayhurn, P. Zinc-α2-glycoprotein: An adipokine modulator of body fat mass? Int. J. Obes. (Lond) 2010, 34, 1559–1565. [Google Scholar] [CrossRef] [Green Version]
  131. Carpéné, C.; Boulet, N.; Chaplin, A.; Mercader, J. Past, Present and Future Anti-Obesity Effects of Flavin-Containing and/or Copper-Containing Amine Oxidase Inhibitors. Medicines 2019, 6, 9. [Google Scholar] [CrossRef] [Green Version]
  132. Severo, J.S.; Morais, J.B.S.; Beserra, J.B.; Dos Santos, L.R.; de Sousa Melo, S.R.; de Sousa, G.S.; de Matos Neto, E.M.; Henriques, G.S.; do Nascimento Marreiro, N.D. Role of Zinc in Zinc-α2-Glycoprotein Metabolism in Obesity: A Review of Literature. Biol. Trace. Elem. Res. 2020, 193, 81–88. [Google Scholar] [CrossRef] [PubMed]
  133. Al-Timimi, D.J.; Sulieman, D.M.; Hussen, K.R. Zinc status in type 2 diabetic patients: Relation to the progression of diabetic nephropathy. J. Clin. Diagn. Res. 2014, 8, CC04–CC08. [Google Scholar] [CrossRef] [PubMed]
  134. Fukunaka, A.; Fujitani, Y. Role of Zinc Homeostasis in the Pathogenesis of Diabetes and Obesity. Int. J. Mol. Sci. 2018, 19, 476. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  135. Olechnowicz, J.; Tinkov, A.; Skalny, A.; Suliburska, J. Zinc status is associated with inflammation, oxidative stress, lipid, and glucose metabolism. J. Physiol Sci. 2018, 68, 19–31. [Google Scholar] [CrossRef] [Green Version]
  136. Ranasinghe, P.; Pigera, S.; Galappatthy, P.; Katulanda, P.; Constantine, G.R. Zinc and diabetes mellitus: Understanding molecular mechanisms and clinical implications. Daru 2015, 17, 44. [Google Scholar] [CrossRef] [Green Version]
  137. Qiu, Q.; Zhang, F.; Zhu, W.; Wu, J.; Liang, M. Copper in Diabetes Mellitus: A Meta-Analysis and Systematic Review of Plasma and Serum Studies. Biol. Trace. Elem. Res. 2017, 177, 53–63. [Google Scholar] [CrossRef]
  138. Yang, H.; Ralle, M.; Wolfgang, M.J.; Dhawan, N.; Burkhead, J.L.; Rodriguez, S.; Kaplan, J.H.; Wong, G.W.; Haughey, N.; Lutsenko, S. Copper-dependent amino oxidase 3 governs selection of metabolic fuels in adipocytes. PLoS Biol. 2018, 16, e2006519. [Google Scholar] [CrossRef]
  139. Tanaka, A.; Kaneto, H.; Miyatsuka, T.; Yamamoto, K.; Yoshiuchi, K.; Yamasaki, Y.; Shimomura, I.; Matsuoka, T.A.; Matsuhisa, M. Role of copper ion in the pathogenesis of type 2 diabetes. Endocr. J. 2009, 56, 699–706. [Google Scholar] [CrossRef] [Green Version]
  140. Squitti, R.; Mende, A.J.; Simonelli, I.; Ricordi, C. Diabetes and Alzheimer’s Disease: Can Elevated Free Copper Predict the Risk of the Disease? J. Alzheimers. Dis. 2017, 56, 1055–1064. [Google Scholar] [CrossRef] [Green Version]
  141. Rajpathak, S.N.; Crandall, J.P.; Wylie-Rosett, J.; Kabat, G.C.; Rohan, T.E.; Hu, F.B. The role of iron in type 2 diabetes in humans. Biochim. Biophys. Acta 2009, 1790, 671–681. [Google Scholar] [CrossRef]
  142. Dutra, F.; Knudsen, F.S.; Curi, D.; Bechara, E.J. Aerobic oxidation of aminoacetone, a threonine catabolite: Iron catalysis and coupled iron release from ferritin. Chem. Res. Toxicol. 2001, 14, 1323–1329. [Google Scholar] [CrossRef] [PubMed]
  143. Rajpathak, S.; Ma, J.; Manson, J.; Willett, W.C.; Hu, F.B. Iron intake and the risk of type 2 diabetes in women: A prospective cohort study. Diabetes Care 2006, 29, 1370–1376. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  144. Kobayashi, M.; Suhara, T.; Baba, Y.; Kawasaki, N.K.; Higa, J.K.; Matsui, T. Pathological Roles of Iron in Cardiovascular Disease. Curr. Drug. Targets. 2018, 19, 1068–1076. [Google Scholar] [CrossRef] [PubMed]
  145. Aigner, E.; Feldman, A.; Datz, C. Obesity as an emerging risk factor for iron deficiency. Nutrients 2014, 6, 3587–3600. [Google Scholar] [CrossRef] [PubMed]
  146. Yang, L.; Chen, Y.; Lu, M.; Liu, L.; Shi, L. Association between serum Fe levels and obesity: A meta-analysis. Nutr. Hosp. 2015, 31, 2451–2454. [Google Scholar] [PubMed]
  147. Hu, Z.; Chen, J.; Sun, X.; Wang, L.; Wang, A. Efficacy of vitamin D supplementation on glycemic control in type 2 diabetes patients: A meta-analysis of interventional studies. Medicine (Baltimore) 2019, 98, e14970. [Google Scholar] [CrossRef] [PubMed]
  148. Berridge, M.J. Vitamin D deficiency and diabetes. Biochem. J. 2017, 474, 1321–1332. [Google Scholar] [CrossRef]
  149. Nakashima, A.; Yokoyama, K.; Yokoo, T.; Urashima, M. Role of vitamin D in diabetes mellitus and chronic kidney disease. World J. Diabetes 2016, 7, 89–100. [Google Scholar]
  150. Sturza, A.; Văduva, A.; Uțu, D.; Rațiu, C.; Pop, N.; Duicu, O.; Popoiu, C.; Boia, E.; Matusz, P.; Muntean, D.M.; et al. Vitamin D. improves vascular function and decreases monoamine oxidase A expression in experimental diabetes. Mol. Cell. Biochem. 2019, 453, 33–40. [Google Scholar] [CrossRef]
  151. Carpéné, C.; Mercader, J.; Le Gonidec, S.; Schaak, S.; Mialet-Perez, J.; Jakaroff-Girard, A.; Galitzky, J. Body fat reduction without cardiovascular changes in mice after oral treatment with the MAO inhibitor phenelzine. Br. J. Pharmacol. 2018, 175, 2428–2440. [Google Scholar]
  152. Carpéné, C.; Gómez-Zorita, S.; Chaplin, A.; Mercader, J. Metabolic Effects of Oral Phenelzine Treatment on High-Sucrose-Drinking Mice. Int J. Mol. Sci. 2018, 19, 2904. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  153. Mercader, J.; Sabater, A.G.; Le Gonidec, S.; Decaunes, P.; Chaplin, A.; Gómez-Zorita, S.; Milagro, F.I.; Carpéné, C. Oral Phenelzine Treatment Mitigates Metabolic Disturbances in Mice Fed a High-Fat Diet. J. Pharmacol. Exp. Ther. 2019, 371, 555–566. [Google Scholar] [CrossRef] [PubMed]
  154. Iqbal, S.; Khan, S.; Naseem, I. Antioxidant Role of Vitamin D in Mice With Alloxan-Induced Diabetes. Can. J. Diabetes 2018, 42, 412–418. [Google Scholar] [CrossRef] [PubMed]
  155. Saedisomeolia, A.; Taheri, E.; Djalali, M.; Djazayeri, A.; Qorbani, M.; Rajab, A.; Larijani, B. Vitamin D status and its association with antioxidant profiles in diabetic patients: A cross-sectional study in Iran. Indian J. Med. Sci. 2013, 67, 29–37. [Google Scholar] [PubMed] [Green Version]
  156. Góth, L.; Nagy, T. Acatalasemia and diabetes mellitus. Arch. Biochem. Biophys. 2012, 525, 195–200. [Google Scholar] [CrossRef]
  157. Goth, L. Catalase Deficiency and Type 2 Diabetes. Diabetes Care 2008, 31, 2008. [Google Scholar] [CrossRef] [Green Version]
  158. Sozmen, B.; Delen, Y.; Girgin, F.K.; Sozmen, E.Y. Catalase and Paraoxonase in Hypertensive Type 2 Diabetes Mellitus: Correlation with Glycemic Control. Clin. Biochem. 1999, 32, 423–427. [Google Scholar] [CrossRef]
  159. Kechrid, Z.; Hamdi, M.; Nazıroğlu, M.; Flores-Arce, M. Vitamin D supplementation modulates blood and tissue zinc, liver glutathione and blood biochemical parameters in diabetic rats on a zinc-deficient diet. Biol. Trace Elem. Res. 2012, 148, 371–377. [Google Scholar] [CrossRef]
  160. Jakobsen, J.; Knuthsen, P. Stability of vitamin D in foodstuffs during cooking. Food Chem. 2014, 148, 170–175. [Google Scholar] [CrossRef]
  161. Jayasena, D.D.; Jung, S.; Kim, S.H.; Kim, H.J.; Alahakoon, A.U.; Lee, J.H.; Jo, C. Endogenous functional compounds in Korean native chicken meat are dependent on sex, thermal processing and meat cut. J. Sci. Food. Agric. 2015, 95, 771–775. [Google Scholar] [CrossRef]
  162. The U.S. Department of Agriculture’s (USDA’s). FoodData Central. National Nutrient Database for Standard Reference Legacy, Nutrients: Caffeine. 2018. Available online: https://fdc.nal.usda.gov (accessed on 14 April 2020).
  163. Foodb. Compound L-Histidine FDB011856. 2019. Available online: https://foodb.ca/compounds/FDB011856 (accessed on 14 April 2020).
  164. The U.S. Department of Agriculture’s (USDA’s). FoodData Central. Zinc. 2019. Available online: https://fdc.nal.usda.gov (accessed on 14 April 2020).
  165. The U.S. Department of Agriculture’s (USDA’s). FoodData Central. Copper. 2019. Available online: https://fdc.nal.usda.gov (accessed on 14 April 2020).
  166. The U.S. Department of Agriculture’s (USDA’s). FoodData Central. USDA National Nutrient Database for Standard Reference, Iron, Release 28 October 22, 2015 11:13 EDT. Available online: https://fdc.nal.usda.gov (accessed on 14 April 2020).
  167. The U.S. Department of Agriculture’s (USDA’s). FoodData Central. Vitamin D. 2019. Available online: https://fdc.nal.usda.gov (accessed on 14 April 2020).
Figure 1. An illustration of the role of natural agents on SSAO activity throughout the supplementation of creatine in T2DM patients. Upregulation of SSAO activity and creatine related methylamine production which is a substrate of SSAO elevates formaldehyde, ammonia, and H2O2 in T2DM patients which causes possible complications; Additional ingestion of natural agents capable to inhibit increased SSAO activity diminishes the production of formaldehyde, ammonia, and H2O2 and risks of possible complications are reduced. Notes: T2DM, type 2 diabetes mellitus; SSAO, semicarbazide-sensitive amine oxidase; ↑, upregulation; ↓, downregulation; CH3NH2, methylamine; CH2O, formaldehyde; H2O2, hydrogen peroxide; NH3, ammonia.
Figure 1. An illustration of the role of natural agents on SSAO activity throughout the supplementation of creatine in T2DM patients. Upregulation of SSAO activity and creatine related methylamine production which is a substrate of SSAO elevates formaldehyde, ammonia, and H2O2 in T2DM patients which causes possible complications; Additional ingestion of natural agents capable to inhibit increased SSAO activity diminishes the production of formaldehyde, ammonia, and H2O2 and risks of possible complications are reduced. Notes: T2DM, type 2 diabetes mellitus; SSAO, semicarbazide-sensitive amine oxidase; ↑, upregulation; ↓, downregulation; CH3NH2, methylamine; CH2O, formaldehyde; H2O2, hydrogen peroxide; NH3, ammonia.
Molecules 25 02029 g001
Figure 2. (A) The concurrence of certain natural agents in plasma of T2DM patients. (B) The impact of certain natural agents on SSAO activity. Notes: T2DM, type 2 diabetes mellitus; SSAO, semicarbazide-sensitive amine oxidase; Cu, copper; ZAG, zinc-α2-glycoprotein; Zn, zinc; Fe, iron; ↑, upregulation; ↓, downregulation; ――, direct or indirect involvement in SSAO activity; ……, possible involvement in SSAO activity.
Figure 2. (A) The concurrence of certain natural agents in plasma of T2DM patients. (B) The impact of certain natural agents on SSAO activity. Notes: T2DM, type 2 diabetes mellitus; SSAO, semicarbazide-sensitive amine oxidase; Cu, copper; ZAG, zinc-α2-glycoprotein; Zn, zinc; Fe, iron; ↑, upregulation; ↓, downregulation; ――, direct or indirect involvement in SSAO activity; ……, possible involvement in SSAO activity.
Molecules 25 02029 g002
Table 1. Major dietary sources of creatine.
Table 1. Major dietary sources of creatine.
Creatine Natural and Synthesized SourcesMajor SourcesReferences
Creatine dietary sourcesRed meatPost et al. [46]
Kreider et al. [47]
Dairy products
Seafood
Creatine supplementsCreatine monohydrateInácio [48]
Buford et al. [49]
Creatine nitrateGalvan et al. [44]
Creatine hydrochlorideGufford et al. [50]
Creatine ethyl esterGufford et al. [51]
Buffered creatineJagim et al. [52]
Liquid creatineGill et al. [53]
Creatine magnesium chelateSelsby et al. [54]
Table 2. Impact of caffeine and creatine separate consumption on healthy and diabetic conditions.
Table 2. Impact of caffeine and creatine separate consumption on healthy and diabetic conditions.
CompoundsHealthy Humans/Animal ModelsType 2 Diabetes Mellitus – Humans
Weight-GainWeight-Loss(↑) SSAO Upregulation(↓) SSAO InhibitionWater-RetentionIncreased Urinary-ExcretionErgogenic Effect Reducing Insulin SensitivityImproving Glucose ToleranceAnti-Hyperglycemic EffectImpairing Kidney Function
CreatineYes [105] humanNo [105] humanYes [21] animal (healthy)No [21] animal (healthy)Yes [105] humanNo [105] humanYes [106] human (healthy)No [70] human (healthy)Yes [70] human (healthy)Yes [64]No [61]
CaffeineNo [107] humanYes [107] humanNo [68] animalYes [68] animalNo [108] humanYes [108] humanYes [109] humanYes [110] animalNo effect on healthy animals Yes (in diabetic animals) [111]Yes [82]
No [86]
Yes [105]
No [84]
Notes: SSAO, semicarbazide-sensitive amine oxidase; ↑, upregulation; ↓, downregulation.
Table 3. Studies including treatment with the combination of Creatine-Caffeine in healthy, non-diabetic subjects/animals.
Table 3. Studies including treatment with the combination of Creatine-Caffeine in healthy, non-diabetic subjects/animals.
Title of StudyStudy ObjectUsed DosesSummaryReferences
Caffeine is ergogenic after supplementation of oral creatine monohydrateHumansCreatine - 0.3 g/kg/day
Caffeine - 5 mg/kg/day
Caffeine ingestion has an ergogenic effect in trained males after 6 days of creatine loading administration and caffeine abstinenceDoherty et al. [96]
Effect of caffeine ingestion after creatine supplementation on intermittent high-intensity sprint performanceHumansCreatine - 0.3 g/kg/day
Caffeine - 6 mg/kg/day
Caffeine ingestion after creatine loading for 5 days increased the strength of physically active men as compared to the control group Lee et al. [97]
Effects of coffee and caffeine anhydrous intake during creatine loadingHumansCreatine - 5 g 4 times a day
Caffeine - 300 mg 4 times a day
These findings suggest that neither creatine alone, nor in combination with caffeine or coffee, significantly affected performance compared to placebo.Trexler et al. [99]
The effects of a high dosage of creatine and caffeine supplementation on the lean body mass composition of rats submitted to vertical jumping trainingRatsCreatine - 0.430 g/kg/day (loading), 0.143 g/kg (maintenance)
Caffeine −15 mg/kg/day
Creatine and caffeine combination did not influence on lean body mass in sedentary and exercised rats while caffeine administration reduced fatFranco et al. [102]
Table 4. Major dietary sources of caffeine, histidine, Zn, and vitamin D. Cu-chelators are not presented naturally in food.
Table 4. Major dietary sources of caffeine, histidine, Zn, and vitamin D. Cu-chelators are not presented naturally in food.
Promising Agents to Combine with CreatineMajor Dietary SourcesReferences
CaffeineCoffee[162]
Tea
Cocoa
Chocolates
HistidineMeat and meat products[163]
Grain products
Dairy products
Vegetables
Seafood
Egg
Beans
Nuts
ZnMeat[164]
Legumes
Poultry
Dairy products
Nuts
Seafood
CuLegumes[165]
Mushrooms
Chocolate
Nuts
Beef
Seafood
FeLiver[166]
Beef, pork, lamb
Beans
Cereals
Seafood
Nuts
Peas
Vitamin DFish[167]
Mushrooms
Egg
Liver
Beef
Chicken breast
Dairy products
Soybeans

Share and Cite

MDPI and ACS Style

Papukashvili, D.; Rcheulishvili, N.; Deng, Y. Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus. Molecules 2020, 25, 2029. https://doi.org/10.3390/molecules25092029

AMA Style

Papukashvili D, Rcheulishvili N, Deng Y. Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus. Molecules. 2020; 25(9):2029. https://doi.org/10.3390/molecules25092029

Chicago/Turabian Style

Papukashvili, Dimitri, Nino Rcheulishvili, and Yulin Deng. 2020. "Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus" Molecules 25, no. 9: 2029. https://doi.org/10.3390/molecules25092029

Article Metrics

Back to TopTop